



ASX Announcement

CogState and Merck Canada Partner to Bring Proprietary Test for Assessing Patient Cognitive Function to Canadian Physicians

Highlights

- CogState has entered into a promotion agreement with Merck Canada for the exclusive right to market and promote the CogState Test in Canada.
- The CogState Test is validated and can detect and monitor changes in cognitive function indicative of neuro-degenerative conditions including Alzheimer's disease and mild cognitive impairment.

Melbourne, **Australia** June 25, 2012 –**CogState Ltd (ASX:CGS)** today announced it has entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote the CogState Test in Canada. The first commercial sale is expected to occur before the end of 2012.

The CogState Test assesses cognition in patients and the reports generated on the basis of this assessment can allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer's disease. The CogState Test can also be used to monitor changes in cognitive function following concussion or after treatment with drugs or other types of interventions.

The partnership between CogState and Merck will provide Canadian physicians with a tool to help them with early detection of cognitive decline in their patients. "We believe that with CogState and Merck working together, Canadian patients can benefit from expanded cognitive assessment capability in the marketplace," said Christian Sauvageau, Vice President of Customer Innovation Solutions for Merck Canada. "This partnership is part of Merck's ongoing commitment to finding treatments for diseases involving the central nervous system."

"The agreement with Merck Canada represents the first stage of commercialising the CogState Test in general practice medicine," said Brad O'Connor, Chief Executive Officer of CogState. "It is an important milestone in the company's strategy to establish the CogState Test as the gold standard for measuring cognitive change and making it a routine part of wellness care around the world."

"CogState's Test allows for regular and standardised testing of cognitive function to detect even subtle change that could signify the earliest stage of dementia," Mr. O'Connor said. "We are delighted to be partnering with Merck Canada, a leading healthcare company, with expertise in delivering innovative health solutions to Canadians. We are confident that Merck Canada provides a robust base to begin selling our product in Canada, an important target market," concluded Mr. O'Connor.



Investor Conference Call

An investor conference call will be held today, Monday 25th June at 11.00am AEST, with Brad O'Connor, Chief Executive of CogState Limited.

Conference ID: 9470 5443

Australia	1800 123 296
Hong Kong	800 908 865
Japan	0120 985 190
New Zealand	0800 452 782
Singapore	800 616 2288
United Kingdom	0808 234 0757
United States	1855 293 1544

For further information:

Please contact:

Haley Price
Buchan Consulting Account Manager
+61 3 9866 4722 or 0423 139 163
hprice@buchanwe.com.au

Brad O'Connor
CogState Chief Executive Officer
+61 3 9664 1300 or 0411 888 347
boconnor@cogstate.com